Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF plus peginterferon alfa-2a versus monotherapy in non-cirrhotic chronic hepatitis B
NL-OMON39436Phase 4Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon alfa and tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (4 arms), sponsored by Gilead Sciences. Primary endpoint: HBsAg loss at Week 72. Started Jun 2011; status: active, not recruiting.
02
Drugs
interferon alfatenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON39436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39436.